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Country Report China – Stem Cell Research 
 
 
Rosemann, A; Zhang, XX; Sui, SL; Su, YY, and A. Ely (2013)  
 
Introduction  
 
This paper provides an overview of the regulatory, funding and institutional landscape 
of stem cell research in the People’s Republic of China. The document is structured in 
two parts and three appendices. PART I provides an overview of the current funding 
landscape for stem cell research in China. It introduces, furthermore, some of the key-
projects that have been funded by the Chinese government in recent years, and key-
priority areas in the regenerative stem cell field in the recent past, the present and 
future. PART II provides an overview of the regulatory situation for stem cell 
research. We have listed (1) regulations for basic research, (2) the regulations for 
clinical research on human subjects in China (these regulations do not explicitly 
address clinical stem cell research, but they constitute a set of horizontal regulations 
that affect experimentations with stem cell-based applications indirectly). Thereafter 
(3) the regulatory approach for clinical research and applications with stem cells will 
be explored. An overview will be provided of the currently existing regulatory steps 
and documents, and some commentary on implementation is provided, if possible. 
The final appendix provides information on: (1) Key state institutions that affect stem 
cell research in China. (2) Key research institutes and stem cell biobanks in China. (3) 
A list of clinics that offer experimental stem cell therapies in China.   
 
PART I: The funding landscape: a provisional sketch 
 
During the last three decades, the promotion of innovation processes in science and 
technology has been defined as a key driver for economic development in China. 
China has surpassed Japan as the second largest investor of R&D expenditures in 
2006 (US NSF 2012). Drug discovery and regenerative medicine, as has been re-
emphasized by premier Wen Jiabao in January 2012, form two key-strategic areas of 
investment (Qiu 2012).  
According to the Cure Report – a 2009 report from the UK Medical Research 
Council on Sino-UK research collaborations in biomedicine and the biosciences – the 
Chinese government has between 2005 and 2010 spent between RMB 500 million 
(USD 63m) and RMB 2 billion (USD 250m) into the development of SC research. 
The UK in contrast, invested in the two-year period 2006-2007 GBP 30 million (ca. 
USD 43m) (Cure 2009). 
Since the Ninth Five-Year Plan (1997-2001) stem cell research has been 
endorsed by several governments departments. The largest part of funding has been 
provided by the National Science Program of the Ministry of Science and 
Technology, with the "863" program targeting the promotion of high technology 
research, and the "973" program focusing on the promotion of basic research (in all 
fields of science) (Cure 2009). 
However, grants for stem cell research were also allocated through the 
Chinese Academy of the Sciences, the National Natural Science Foundation 
Committee, and other government related departments and organizations (Cure 2009). 
In the Eleventh Five Five-Year Plan (2007-2011) the “863” program included a 
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funding section for “Stem Cells and Tissue Engineering”, within a wider program that 
aimed to the development of biological and pharmaceutical technology (China 
National Center for Biotechnology Development 2011a). This program finished in 
2011, with the following PIs having been awarded major grants: ZHOU Qi, WANG 
Changyong, MA Yue, WU Fang, WANG Yan, LI Lingsong, WANG Ren (ibid.). 
In the context of the Twelfth Five-Year Plan (2012-2016), the "stem cell 
therapy clinical translational and applied research program” has been initiated, with 
money allocated through the “863” program (MOST 2013).  
Another important measure for the promotion of stem cell research, has been 
the formation of the National Stem Cell Advisory Committee (???????????
???), by the Ministry of Science and Technology in October 2011 (Wang 2011). 
Through this committee, the ministry aims to: 
(1) Further coordinate stem cell research, to make strategic funding decisions (to 
increase efficiency of the use of national funding resources) 
(2) To further create a favourable environment for innovation, to promote high-
level training  
(3) To strengthen international collaborations, and exchanges, so as to stimulate 
research into major scientific issues, and major technical breakthroughs  
 
A closely related initiative, also funded by MOST, is the formation of biobanks, 
which has been set as a key-target in the Twelfth Five Year Plan (2012-2016) (China 
National Center for Biotechnology Development 2011b).  
More specifically, the plan emphasizes the construction of biobanks as repositories 
for genetic clinical specimen, to: 
o develop drug research / pharmaceuticals and for purposes of 
development biomedical engineering products, as well as for biological 
breeding.  
 
A standardized clinical information database and biological specimen database shall 
be established in this respect in Beijing, administered under the Beijing Municipal 
Science and Technology Commission. The bio-bank shall be hosted by the Capital 
Medical University. It shall form a repository that contains samples of major disease 
transmitters (hope have understood this correctly), clinical data and other biological 
samples (China National Center for Biotechnology Development 2011b).   
Furthermore, four national level stem cell banks have been founded under the 
Chinese Academy of the Sciences (ibid.):  
- (1) Beijing Municipality Stem Cell Bank 
- (2) Southern Stem Cell Bank, in Guangzhou 
- (3) Stem cell bank of the Chinese Academy of the Sciences, Shanghai 
- (4) East China Stem Cell Bank (also in) Shanghai 
One of the authors of this report was in 2008 reported, furthermore, that a five-year 
government grant was provided for the foundation of five human embryonic stem cell 
banks. One of these five banks, in Changsha, should be specialized in the banking of 
disease-specific stem cells lines. The current status and exact functions of these banks 
would have to be explored in further research.   
An open question is at this moment also what the role (a) of provincial and 
municipal governments is in funding stem cell research. Unclear is furthermore, the 
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role of (b) foundations and (c) private investors and companies, in the financiering of 
translational stem cell research and/ or experimental for-profit clinical applications. 
Regarding the latter group, private investors and companies, active investment 
activity can be expected, since the application of (non-systematically proven or 
completely unproven) experimental stem cell therapies, constitute important market 
opportunities in China.  
 
PART II: Regulatory Situation  
 
I. Basic Research  
 
The following regulations have been issued in China, to govern basic research with 
stem cells. Both of these regulations focus on human embryonic stem cell research 
only. The first concerns the sourcing of human embryos and ova in the context of IVF 
clinics. The second addresses the specific conditions under which human embryos can 
be produced and used for research. No regulation exists currently that addresses (a) 
somatic cell nuclear transfer techniques for research purposes (i.e. “therapeutic 
cloning”), (b) basic or preclinical research with iPS cells, and (c) research with 
human-animal hybrids. 
 
(1) 2001-2003, MOH: The Ethics Guiding Principles for Assisted Reproductive 
Technology 
 
This regulation addresses stem cell research, by stipulating that all ART institutions 
must set up ethics committees, and that these committees must approve applications 
of human embryos to be donated for research (Hu, Min and Wei 2011; Cure 2009). 
The regulation affects the supply of embryos, ova and fetal tissue for research also in 
the following ways: (i) by stating that the buying and selling of human eggs, embryos 
or fetal tissues is prohibited, (ii) by restricting the use of embryos for research to 
super-numerous embryos in the context of an IVF treatment, and by explicitly 
prohibiting the creation of IVF embryos for research only, (iii) by specifying that 
embryos and gametes must be voluntarily donated, on the basis of informed consent, 
and (iv) by forbidding hormonal super-stimulation, to harvest more eggs. This 
regulation is backed up by punitive measures: IVF clinics or ART centers can loose 
their license if they violate these guidelines (Cure 2009). 
 
(2) 2003, MOH/MOST: The Ethics Guiding Principles for hESC research  
《⼈人胚胎⼲干细胞研究伦理指导原则》 
Human embryonic stem cell (hESC) research is regulated with these principles at a 
national level, through ministerial guidelines. The core aspects of this regulation are 
that: (i) embryos are not allowed to be used for hESC after 14 days post conception, 
(ii) embryos used for research can not be implanted in human beings (prohibition of 
human reproductive cloning). The principles demand, furthermore, that institutions 
that are involved in hESC form an ethics committee that details regulatory rules and 
exact conditions under which research can be conducted.  
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Criticism of existing basic research regulation from the National Ethics 
Committee of the MOH  
 
These principles have been criticized by the National Ethics Committee of the MOH 
in China because (a) they do not introduce a registration or licensing system of 
research institutes or clinics that conduct hESC research, (b) because they are not 
backed up by law, and (c) no clear control pathways for the principles are provided. 
Plans and efforts to revise this regulation, from the side of the MOH National Ethics 
Committee, are ongoing (Zhai 2007). 
 
 
II. Clinical Research 
 
It follows now an overview of the regulations, laws and institutions, that play a role 
(or are foreseen to play a role) for clinical stem cell research. This process is still 
evolving. Before briefly discussing this regulatory approach, I will introduce however 
an overview of the regulations and laws that govern research on human subjects in 
China, of which some do – indirectly – also impact on experimental clinical research 
and applications.   
 
II.a. Regulations for human subject research (affects clinical SC 
research horizontally) 
 
The following provides an overview of existing regulations for human subject 
research. These regulations are not designed for clinical trials with stem cells, but they 
affect clinical research that involves stem cell-based applications indirectly (i.e. as 
horizontal regulations).  
 
(1) Review of clinical research and review by Ethics Committees / hospital-
internal IRBs 
 
(a) Foundation of a national-level ethics committee 
 
The MOH ‘Ethics Committee on Biomedical research involving human subjects’ was 
founded in 1998, and renamed in 2000 as ‘Medical Ethics Expert Committee’. The 
committee comprises since a reform in 2007 – 17 members from multi-disciplinary 
background.  
 
(b) The 2007 ‘Regulation on ethical review of biomedical research involving 
human subjects’ 《涉及⼈人的⽣生物医学研究伦理审查办法（试⾏行）》 
 
A draft regulation on Ethical Review of Medical Research involving human subjects 
was drafted in 1998, but was due to controversies failed to be endorsed (Hu, Min and 
Wei 2011). It was issued by the MOH only in 2007. According to this regulation – all 
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– research on human subjects has to occur under review of ethics committees at the 
level of research institutes and hospitals. It specifies details for how informed consent 
procedures have to be structured. This regulation is of fundamental importance to 
clinical stem cell research and applications, because it requires mandatory EC 
approval at the level of medical institutions that engage in these activities.  
 
(2) The 1994 Regulation on the Government of Medical Institutions 
 
This regulation has been passed by the state council in 1994. It clarifies that informed 
consent is required for performance of surgical operations, special investigations, and 
special (experimental) treatments. It sets out, furthermore, a number of rules for 
medical institutions, such as for instance, that approval documents for treatments, can 
not be ‘inherited’, if the owner, or name of a hospital changes. This regulation is of 
some relevancy for clinical SC research, in particular institutes that offer for-profit 
therapies. The Jilin Silicon Valley Hospital, for instance, was criticized by the media 
on the basis of this regulation. Reason: the hospital had changed its name and 
proprietor, but the same approval license was used (issued by a local and a provincial 
health bureau) to attract patients (approval documents were publicly displayed on the 
internet). 
 
(3) The 1999 Drug Clinical Trial Regulations Law on Practicing Doctors 
 
This regulation protects patients by stating that doctors who violate a patient’s privacy 
or conduct experimental interventions without informed consent, will be legally 
persecuted. I have not yet heard of cases where this regulation was applied, in the 
context of SC based for experimental treatments. In theory, however, this regulation 
applies to doctors who fail to sufficiently inform patients, or who violate a patient’s 
privacy (Cure 2009). In other words, patients could sue doctors who offered 
experimental stem cell treatments based on fraudulent claims, on the basis of this 
regulation.  
 
(4) The 2001/2001 Drug Administration Law / Regulations for implementation of 
the drug 
 
This law has been passed by the National People’s Congress. It covers the use of 
pharmaceutical products in research as well as practice. It clarifies that GCP and 
GMP standards must be followed. (Cure 2009). 
This regulation (if I understand it correctly – need for verification by CIs in 
China) is of relevancy to hospitals that conduct clinical trials with SC in the context of 
an SFDA monitored IND application. These hospitals would, according to this 
regulation require GCP certification, obtained through the procedures set out above. 
Other clinical trials or forms of experimentation – that are conducted outside of the 
jurisdiction of the SFDA do – not require to be carried out in GCP accredited 
hospitals, and the regulation is for these hospitals redundant.  
 
(5) The 1999-2003 SFDA good clinical practice standards (药物临床试验质量管理
规范) 
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These SFDA GCP standards were issued in a first version in 1999, and in a second 
more complete version in 2003. Both were issued by the SFDA. The SFDA GCP 
standards specify procedures for the accreditation of medical institutions, to take part 
in drug trials. They require that each hospital in human subject research acquire GCP 
certification (Cure 2009). An interesting feature is that GCP certification is based on 
examinations of high-level clinical staff (heads of department). They emphasize strict 
informed consent and strict review by ethics committees, and include provisions on 
how IRBs should be composed and be organized. The Chinese GCP standards, draw 
actively on the now internationally handled ICH GCP standards. (Cure 2009). These 
SFDA GCP standards are of relevancy to hospitals that conduct clinical trials with SC 
in the context of an SFDA registered IND application.  
 
II. b. The evolving regulatory approach for clinical SC research  
 
It follows now an overview of the evolving regulatory approach for clinical SC 
research and applications in China. Three regulatory documents shall be discussed: 
(1) The 2009 May 1 Regulation; (2) a 2010 draft regulation; (3) the January 6 2012 
notification for clinical stem cell research and application.   
 
1. The ‘May 1 2009 regulation’ and its impact 
 
On May 1 2009 the MOH promulgated the “Management Measures for the Clinical 
Use of Medical Technologies” [医疗技术临床应用管理办法], a regulation that 
classified a range of new medical technologies and procedures into three categories. 
Stem cell transplant technology was grouped into category III, which included 
technologies considered as risky, ethically controversial and in need of clinical 
verification (Chen 2009). To implement the regulation the MOH assigned five 
institutions (ibid.: 271), among them the Chinese Medical Association, the Chinese 
Hospital Association and the Chinese Doctors Association. According to an associate 
of the MOH in Beijing, clinics that used SC transplantation technology were 
summoned to register at these institutions. These organizations in turn were assigned 
to grant licenses on the basis of newly formed assessment criteria and review and 
inspection committees. In practice, this regulation has not yet been implemented for 
SC transplantation technologies. As stated by a senior SC scientist, who as a member 
of the Chinese Doctors Association was involved in the formulation of review criteria, 
there were widespread disagreements among experts of the assigned five institutions, 
over the precise characteristics of these criteria, over feasible implementation 
pathways, as well as the extent to which the situation should be controlled.  
 
2. The 2010 Draft Regulation 
 
In 2008 the Science and Education unit of the MOH authorized an expert committee 
of medical ethics chaired by Prof Chingli Hu, to develop a comprehensive draft 
regulation for clinical research and applications with human SC in China. After a two-
year consultation and preparation process, a draft was submitted to the MOH in 
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October 2010. This proposal has subsequently been under internal consideration, and 
is expected to form the foundation of a finalized version that is expected soon.1  
A central premise of this draft is the promotion of standardized and rigorous 
scientific forms of clinical SC research (Hu 2010: 27). It asks for methodical 
preclinical studies and the generation of reliable safety data, as well as standardized 
clinical trials that precede clinical applications (27). These trials shall be subject to 
approval and review procedures under the MOH and the SFDA (which since 2008 has 
been a subunit of the MOH). Only qualified and licensed hospitals would be able to 
provide approved clinical applications (37). Furthermore, the draft stipulates that the 
quality and safety of used cells must be subjected to reliable controls and 
documentation (32). Medical institutions that violate these principles will be forced to 
stop SC-based clinical trials or applications for a period of five years (37).  
The draft specifies approval and review procedures for three central forms of 
clinical research and applications with SC. First is approval of clinical trials and 
applications of stem cell based drug products, i.e. standardized batch products based 
on amplification of cells from one or multiple donors. Responsibilities for evaluation 
and market approval of these ‘off-the-shelf’ SC products (commonly regarded as the 
most risky treatment form with SC) shall be handled by the SFDA, and be based on 
systematic preclinical studies and closely reviewed Phase I-III clinical trials (36). 
Second is approval of clinical trials and applications of modified SC from a single 
donor to single recipient. With reference to the 2009 regulation these treatment forms 
were defined as medical technology. Regulatory distinctions are made in this respect 
between autologous/allogeneic SC, and minimally/extensively manipulated SC. 
Approval of minimally processed autologous SC, which are seen as the least risky 
group of cells, shall occur through the MOH Bureau of Medical Administration. More 
extensively manipulated cells, particularly from allogeneic sources, shall be approved 
by the MOH Bureau of Science and Education. Application and review procedures 
shall be handled by the thirty-one province-level sub-branches of the MOH, with the 
MOH in Beijing as the central supervising agency. Third is approval of experimental 
therapeutic approaches with SC. Experimental for-profit applications shall be strictly 
delimited. In accordance with article 35 of Helsinki Declaration first-in-human 
experimental treatments with SC shall be allowed, but in a low number of patients, 
and according to clear approval criteria. Applications and oversight shall occur 
through specialized ethics committees, at the provincial MOH branches. 
With this draft regulation, a clear step toward international harmonization has 
been set into motion. In regulating medical procedures with SC proportionate to risk, 
for example, the Chinese draft regulation follows essentially the approach that is also 
taken in the EU (Faulkner 2009: 641). Differences exist, however, with respect to 
terminology and the allocation of responsibilities. In the EU, all experimental medical 
procedures with SC (including autologous SC for non-homologous use) have since 
2007 been classified as advanced therapy medicinal products. These are regulated 
under the centralized auspice of the European Medicines Agency (EMA) (ibid. 2009; 
EMA 2012). The 2010 draft regulation for China, on the other hand, follows a slightly 
different strategy. For one thing, approval procedures are divided between the 
categories ‘medical products’ and ‘medical technologies. For the other thing, 
responsibilities are not done by a centralized drug regulatory agency, but split across 
three administrational units of the MOH, each with its own subsidiary branch 
                                                
1 This information is based on a presentation of this draft regulation, generously provided by Prof 
Chingli Hu and his team in Shanghai, on January 21, 2011. 
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organizations at a provincial level. Since the draft regulation is likely to still undergo 
significant revisions, it is too early to say what the implications of these differences 
for processes of regulatory harmonization and international collaborations will be. 
Further research into these directions, together with a focus on local implementation, 
will be of interest.  
 
 
 
 
3. The January 2012 notification 
 
On January 6 2012, the MOH issued a regulatory document called ‘Notification on 
Self-Evaluation and Self-Correction Work regarding the Development of Clinical 
Stem Cell Clinical Research and Applications’ [关于开展干细胞临床研究和应用自查自纠
工作的通知].2	 With this document an initial one-year phase of a more comprehensive 
regulatory approach has been initiated, whose precise details have not yet been 
publicized. In the January 2012 document, four subsequent stages of this forthcoming 
approach have been announced: self-evaluation (zicha), self-correction (zijiu), re-
certification (chongxin renzheng), and standardized management (guifan guanli).  
The initial one-year phase that is set out in the 2012 document, however, 
addresses only the first two of these stages: self-evaluation and self-correction. Self-
evaluation of the hospitals that carry out SC-based clinical research and applications 
shall occur in the following way. First, clinics are required to fill in the ‘Self-
Evaluation Form for Inquiry into Conditions of Stem Cell Clinical Research and 
Applications’.3 In this form, clinics are asked to report truthfully on previously and 
currently developed kinds of clinical research and applications with stem cells. 
Information is requested on (1) types of cells and forms of cell-processing, (2) the 
disease types for which cells have been used, (3) forms of ethics and regulatory 
approval mechanisms, (4) informed consent procedures, (5) information on risks and 
experienced problems, (6) sources of funding and patient fees, (7) number of patients 
experimentally treated, and (8) publications or summarizing reports from clinical 
trials or other types of clinical studies. Second, this information is evaluated by 
province-level MOH workgroups, which are coordinated by the ‘Stem Cell Clinical 
Research and Application Standardization and Rectification Work and Leadership 
Group’, co-founded by the MOH and SFDA in Beijing (paragraph 2). The task of 
these province-level workgroups is to appraise the incoming data, to produce 
summarizing reports to Beijing (paragraph 4), and during later stages, to play an 
active role in the implementation and enforcement of the regulation (paragraph 2).  
Self-correction means that all institutes that have not yet received approval, 
either by the MOH or the SFDA, must stop clinical stem cell research or application 
activities until approval has been obtained. Institutes that continue to carry out 
unauthorized clinical research or applications have been announced to be targeted as 
focal points for rectification (paragraph 2). On the other hand, clinical trials for stem 
cell products that have obtained approval by the SFDA are expected to act in strict 
accordance with the requirements set out by the SFDA, and in compliance with the 
Chinese GCP standards (paragraph 2). The document has announced that no 
                                                
2 http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohkjjys/s3582/201201/53890.htm  
3 This document has been put on the MOH website. 
http://61.49.18.65/publicfiles///business/cmsresources/mohkjjys/cmsrsdocument/doc13829.docx  
Translations of these two documents can be requested from the author of this article per email. 
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registration applications will be accepted by the MOH or the SFDA until July 1 2012 
(paragraph 2). Information on how applications for registration will be handled, 
however, has not been provided in the text. Uncertainty also remains as to how non-
compliance will be dealt with, and which role the MOH and its province-level 
workgroups will play in this. It is not clear, furthermore, whether military hospitals 
(that operate under the command of the Health Department of the Army General 
Logistics Department), will be subjected to the same review and approval procedures 
as state hospitals, or whether a different regulatory approach shall apply.  
 
 
4. The March 2013 announcement of three inter-related draft regulations 
 
On March 7 2013, the MOH has published on its website, three documents that 
summarize, and introduce to the public, the basic structure and central regulatory 
instruments of three inter-related draft regulations, that have been developed by the 
MOH for the regulation of clinical stem cell research and applications, in recent 
months. In contrast to initial media coverage (Zornoza 2013), these documents do not 
constitute the regulatory draft documents themselves, but they provide comprehensive 
summaries of the three draft regulations, that introduce the underlying rationale of the 
forthcoming regulatory framework, its purposes, central regulatory premises, and 
implementation structure. From these documents it becomes clear, that each of the 
three draft regulations, consists of ca 35 to 40 articles, that address different aspects of 
the review and approval procedures, for clinical stem cell research and applications 
(details will follow below).  
The summaries of the draft regulations have been published on the website of 
the MOH for the purpose of public feedback and commentary. The public 
dissemination of the introductory summaries of the three draft regulations, constitutes 
the first publicly visibly step toward regulatory intervention of clinical stem cell 
research and applications in China, since the above-mentioned January 6 2012 
notification. The announcement and summary of the three draft regulations, represent 
the first move toward realization of the third and the fourth of the four regulatory 
phases that were announced by the MOH in the ‘January 6 2012 notification’ (above): 
“re-certification” [chongxin renzheng] and “standardized management” [guifan 
guanli] (following from phases one and two: “self-evaluation” [zicha] and “self-
correction” [zijiu], which were initiated in the course of 2012.  
 
The titles of the three draft regulations are as follows: 
1. Stem cell clinical trial research management methods [ganxibao linchuang 
shiyan yanjiu guanli banfa] 
2. Stem cell clinical trial research basic management methods [ganxibao 
linchuang shiyan yanjiu jidi guanli banfa] 
3. Guidance principles for stem cell preparation, quality control and preclinical 
research [ganxibao zhiji zhiliang kongzhi he linchuangqian yanjiu zhidao 
yuanze]  
 
The most important points in these three documents are as follows: 
 
(1) Approval of stem cell based therapeutic applications must be based on phase I, 
II and III clinical trials 
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(2)  In the context of these trials it will not be allowed to charge patients for 
money 
(3) Clinical trials must be approved by ethics committees, and designed 
specifically administrational units, that involve review by expert committees, 
as formed by provincial and national level units of the MOH, and the SFDA 
(4) Clinical stem cell trials must be based on, and will be approved on the basis 
of, solid preclinical evidence, that established the safety and therapeutic 
potential of a candidate application 
(5) Stem cell clinical trials must be conducted in line with the SFDA’s ‘Good 
Clinical Practice Standards’ (药物临床试验质量管理规范), and related 
regulatory documents 
a. This means that hospitals and/ or departments that conduct stem cell 
trials, must be qualified as GCP hospitals, by the SFDA (will require 
verification) 
(6) Stem cell clinical trials must be conducted in accordance with ethical norms, 
as laid down in the ‘2007 Interim Regulation on the Ethical Review of 
Biomedical Research involving Human Subjects’ (涉及人的生物医学研究伦理
审查办法（试行）), and the Ethics Guiding Principles for hESC research ?人
胚胎干细胞研究伦理指导原则） 
(7) Stem cell collection, separation, purification, amplification, certification, 
packaging, storage and transport of stem cells that are used for clinical trials, 
must occur in accordance with GMP standards.  
a. Staff must be trained in these procedures, and GMP compliance of 
laboratories and related technologies and equipment must be certified 
(8) The regulation applies to all types of stem cell research and regulations, with 
the exception of hematopoetic stem cells, and related products  
(9) Application and review procedures for stem cell clinical trials 
a. Medical institutions must apply at specifically designed report units 
b. The report units distribute the application to the province level 
branches of the MOH and SFDA for formal examination and review 
c. The province level review is followed by a national-level review 
procedure, through the ‘Stem Cell Clinical Research and Application 
Regulation Management Work and Leadership Group’, which is co-
founded by the MOH and SFDA and situated in Beijing (this group is 
also designated in the document as “the office”) 
d. In The Office the application is reviewed by expert committees, and 
experts brings site visits to clinics, as part of the review process 
e. Following this, applications are accepted, or rejected.    
(10) Clinical trials must be conducted in phase I-III format, if there are indicated 
of serious adverse events, these must be reported to Ethics Committees and 
The Office, and the trials must be immediately stopped 
(11) Progress reports of the trials must be submitted to The Office on a 12 months 
basis 
(12) Punishment procedures are specified, that hold institutions and personnel that 
violate regulatory provisions, directly responsible. Legal persecution will 
occur under the existing drug management law.   
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Appendix:  
 
I. Key state institutions that affect stem cell research in China 
 
(1) Ministry of Science and Technology (MOST) / China  
 
(2) The China Centre for Biotechnology Development 
- Has been established under MOST in 1983, to promote innovation processes 
in biotech, and related commercialization. 
- Helps to oversee and handle administrative tasks for MOST, especially in the 
context of the 863 and 973 funding programs. 
- The office for Human Genetic Materials Management is also housed by the 
China Centre for Biotechnology Development.  
 
(3) The Chinese Academy of the Sciences (manages several national key-institutes in 
basic science, among which biology, with a key focus also on disease research and 
drug development) 
 
(4) The Ministry of Health  
- Oversees and funds all forms of clinical research /clinical translation 
processes, as well as clinical applications  
- Medicine research and applications are regulated through three various 
subunits of the MOH 
o The SFDA 
o Bureau of Science and Education (Kejiao Si) 
o Bureau of Medical Administration (Yizheng Si) 
- Since 2009 there is also a new office for the monitoring and registration of 
serious adverse events after approval, which also operates under the 
supervision of the MOH  
 
(5) The Chinese Medical Association (CMA)  
- Plays a leading role in medical education, training and professional exchanges  
- Oversees 82 specialty societies 
- Publishes over 70 medical journals  
- Is also occasionally involved in regulatory processes 
 
Comment: The CMA is to our knowledge currently not involved in the regulation 
or oversight of stem cell-based clinical research. 
 
 
2. Research institutes and stem cell biobanks 
- Four national level stem cell banks under the Chinese Academy of the 
sciences: 
(1) Beijing Municipality Stem Cell Bank 
(2) Southern Stem Cell Bank, in Guangzhou 
(3) Stem cell bank of the Chinese Academy of the Sciences, Shanghai 
(4) East China Stem Cell Bank (also in) Shanghai 
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Clinics that offer experimental for-profit therapies  
 
- Beijing cell permeable rehabilitation center 
- Qingdao SC therapy and rehabilitation center 
- Chongqing stem cell therapy center 
- Beike Biotech 
- Jilin Silicon Valley Hospital  
- Tiantan Puhua Hospital   
- Etc. 
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